Cantor Fitzgerald Maintains Neutral on Amgen, Raises Price Target to $400

Benzinga Newsdesk www.benzinga.com Neutral 59.5%

Neg 0% Neu 59.5% Pos 0%

Cantor Fitzgerald analyst Carter Gould maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $350 to $400.